These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17386285)

  • 1. The TRAVATAN Dosing Aid accurately records when drops are taken.
    Friedman DS; Jampel HD; Congdon NG; Miller R; Quigley HA
    Am J Ophthalmol; 2007 Apr; 143(4):699-701. PubMed ID: 17386285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy and performance of a commercially available Dosing Aid.
    Cronin TH; Kahook MY; Lathrop KL; Noecker RJ
    Br J Ophthalmol; 2007 Apr; 91(4):497-9. PubMed ID: 16916873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops.
    Boden C; Sit A; Weinreb RN
    J Glaucoma; 2006 Feb; 15(1):30-4. PubMed ID: 16378015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid.
    Ajit RR; Fenerty CH; Henson DB
    Eye (Lond); 2010 Aug; 24(8):1338-43. PubMed ID: 20339390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
    Quigley HA; Friedman DS; Hahn SR
    Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chart documentation by general physicians of the glaucoma medications taken by their patients.
    Jampel HD; Parekh P; Johnson E; Miller R
    Am J Ophthalmol; 2005 Aug; 140(2):344-5. PubMed ID: 16086971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
    Robin AL; Novack GD; Covert DW; Crockett RS; Marcic TS
    Am J Ophthalmol; 2007 Oct; 144(4):533-40. PubMed ID: 17686450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma.
    Konstas AG; Tsironi S; Vakalis AN; Nasr MB; Stewart JA; Nelson LA; Stewart WC
    Acta Ophthalmol; 2009 Feb; 87(1):71-6. PubMed ID: 19178390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
    J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata.
    Ochoa BE; Sah D; Wang G; Stamper R; Price VH
    J Am Acad Dermatol; 2009 Sep; 61(3):530-2. PubMed ID: 19700021
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
    Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
    J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication.
    Salyani A; Birt C
    Can J Ophthalmol; 2005 Apr; 40(2):170-4. PubMed ID: 16049530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of opticare eye drop delivery system in patients with rheumatoid arthritis.
    Averns H; Hall J; Webley M
    J Rheumatol; 1999 Dec; 26(12):2615-8. PubMed ID: 10606371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
    Chiselită D;
    Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramadan and eyedrops: the muslim perspective.
    Kumar N; Jivan S
    Ophthalmology; 2007 Dec; 114(12):2356-60. PubMed ID: 18054644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival hyperaemia and other ocular adverse effects on healthy African subjects after single dosing with 0.004% Travoprost.
    Ashaye AO; Adedapo AD; Olusanya BA; Adeoti CO
    Afr J Med Med Sci; 2007 Mar; 36(1):37-42. PubMed ID: 17874490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dosage problems in suspension eyedrops].
    Kwon KA; Diestelhorst M; Süverkrüp R
    Klin Monbl Augenheilkd; 1996; 209(2-3):144-9. PubMed ID: 8992075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.